Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05694533 · ClinicalTrials.gov registry record · Phase 1
Study of Potential CYP3A4 Induction by INDV-2000 in Healthy Adults
A Phase 1 study, sponsored by Indivior.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT05694533 is a Phase 1 study that has completed, run by Indivior. The registered enrollment target is 20 participants.
The verdict
NCT05694533, a Phase 1 study, has completed, sponsored by Indivior.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the potential for cytochrome P450 (CYP) 3A4 induction after dosing with INDV-2000 via use of midazolam as a probe.
Interventions
- DRUG Midazolam
- DRUG INDV-2000
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-03-16 |
| Est. Completion | 2023-05-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05694533
The ClinicalTrials.gov registry entry for NCT05694533 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indivior, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Midazolam is the first listed.
NCT05694533 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05694533 about?
NCT05694533 is a clinical study titled "Study of Potential CYP3A4 Induction by INDV-2000 in Healthy Adults". The purpose of this study is to investigate the potential for cytochrome P450 (CYP) 3A4 induction after dosing with INDV-2000 via use of midazolam as a probe.
What is the current status of trial NCT05694533?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2023-03-16. Estimated completion is 2023-05-01.
What interventions are being tested in trial NCT05694533?
The interventions under investigation include: Midazolam (DRUG), INDV-2000 (DRUG).
Who is sponsoring clinical trial NCT05694533?
This trial is sponsored by Indivior, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.